About this trial
This study focuses on patients who have just been diagnosed with B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy). The goal is to provide the right therapy while doctors figure out the risk level for these conditions. This risk level helps doctors plan the most effective treatment. The study also aims to create a database with important genetic and clinical information about these patients.
The trial's ID number is NCT06289673. This is a Phase 4 trial, which means it looks at the effectiveness and safety of the treatments. It is regulated by the FDA, and around 850 participants are expected to join.
Who can join
Children and young adults aged 1 to 18.99 years can join if they have been diagnosed with acute leukemia or lymphoma. They must have a certain number of cancer cells in their blood or bone marrow. Excluded are those who are pregnant, breastfeeding, or who have had certain prior treatments. The trial team will confirm if someone is eligible to join.
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
The study team makes the final call on eligibility.
What happens in the study
Every participant will receive specific treatments. This includes 7 days of chemotherapy with medications like dexamethasone, vincristine, and daunorubicin for some patients. They will also have an initial lumbar puncture to give additional treatment in the spinal area. After the first week, patients may join another treatment trial or receive different therapy.
Where
This trial is running at 3 locations in the United States. All of them are currently recruiting.
Rady Children's Hospital
San Diego, California
Saint Francis Children's Hospital
Tulsa, Oklahoma
St. Jude Children's Research Hospital
Memphis, Tennessee